Meeting
2019 ASCO Annual Meeting
Minimal residual disease clinical monitoring and depth of response in multiple myeloma.
Authors
Joaquin Martinez-Lopez
Hospital 12 de Octubre, UCSF, San Francisco, CA
Joaquin Martinez-Lopez , Sandy Wai Kuan Wong , Nina Shah , Natasha Bahri , Kaili Zhou , Thomas G. Martin , Jeffrey Lee Wolf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8026)
DOI
10.1200/JCO.2019.37.15_suppl.8026
Abstract #
8026
Poster Bd #
352
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.
First Author: Joaquin Martinez-Lopez
Poster
2017 ASCO Annual Meeting
Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.
First Author: Stefania Oliva
Poster
2023 ASCO Annual Meeting
Patient perspectives on BCMA-targeted therapies for multiple myeloma: A survey conducted in a patient advocacy group.
First Author: Jennifer M. Ahlstrom
Poster
2015 ASCO Annual Meeting
Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody.
First Author: Christopher McCudden